Healthcare entity

Pharmaceutical Benefits Advisory Committee (PBAC)

Company

All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · Pharmaceutical Benefits Advisory Committee (PBAC)

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Pharmaceutical Benefits Advisory Committee (PBAC)

All 1 tracked stories fall under one category: regulation. Australasian Menopause Society is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.7 for that window. We currently track 1 Healthcare story that mention Pharmaceutical Benefits Advisory Committee (PBAC), all published on February 27, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Pharmaceutical Benefits Advisory Committee (PBAC). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Public Advocacy Surge

    Increased media coverage and patient advocacy highlight the pricing disparity between genders.

  2. TGA Approval

    The Therapeutic Goods Administration approves the first female-specific testosterone cream.

  3. Global Consensus Statement

    International medical societies reach consensus on testosterone use for women's sexual health.

Stories mentioning Pharmaceutical Benefits Advisory Committee (PBAC) 1

Health Policy Neutral

Australia's Testosterone Gender Gap: Women Face Higher Costs for Vital Therapy

Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework.

2 sources

Source: theage.com.au · brisbanetimes.com.au

Pharmaceutical Benefits Advisory Committee (PBAC) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.